Tokushige, Katsutoshi
Ikejima, Kenichi
Ono, Masafumi
Eguchi, Yuichiro
Kamada, Yoshihiro
Itoh, Yoshito
Akuta, Norio
Yoneda, Masato
Iwasa, Motoh
Yoneda, Masashi
Otsuka, Motoyuki
Tamaki, Nobuharu
Kogiso, Tomomi
Miwa, Hiroto
Chayama, Kazuaki
Enomoto, Nobuyuki
Shimosegawa, Tooru
Takehara, Tetsuo
Koike, Kazuhiko
Article History
Received: 14 May 2021
Accepted: 14 May 2021
First Online: 17 September 2021
Declarations
:
: Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria, or any other types of remuneration—MSD, Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Lundbeck Japan, AbbVie, Gilead Sciences, Sumitomo Dainippon Pharma, Novo Nordisk, EA Pharma, Astellas Pharma, Mylan, Mochida Pharmaceutical, Kowa Company, Tsumura & CO., and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation)—EA Pharma, Astellas Pharma, Eisai, MSD, Otsuka Pharmaceutical, Suntory Global Innovation Center, Shionogi & Co., Daiichi Sankyo, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb, Mochida Pharmaceutical, Yakult Honsha, AbbVie, Gilead Sciences, Gadelius Medical, Novartis Pharma, Eli Lilly Japan, Mylan N.V., Century Medical, Sogo Rinsho Medefi, Nissan Chemical, Fujirebio. Kowa, Kyokuto Pharmaceutical Industrial. Biofermin Pharmaceutical, and (3) those from which the authors have received individually endowed chair—NichiNichi Pharmaceutical.